Standards and Guidelines for the Interpretation of Sequence Variants: A Joint Consensus Recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular…
By Sue Richards, Nazneen Aziz, S. Bale, D. Bick, Soma Das, J. Gastier-Foster, W. Grody, M. Hegde, E. Lyon, E. Spector and 2 more. 2015
27,617 citations recorded by the source corpus.
Disclaimer: These ACMG Standards and Guidelines were developed primarily as an educational resource for clinical laboratory geneticists to help them provide quality clinical laboratory services. Adherence to these standards and guidelines is voluntary and does not necessarily assure a successful medical outcome. These Standards and Guidelines should not be considered inclusive of all proper procedures and tests or exclusive of other procedures and tests that are reasonably directed to obtaining the same results. In determining the propriety of any specific procedure or test, the clinical laboratory geneticist should apply his or her own professional judgment to the specific circumstances presented by the individual patient or specimen. Clinical laboratory geneticists are encouraged to document in the patient’s record the rationale for the use of a particular procedure or test, whether or not it is in conformance with these Standards and Guidelines. They also are advised to take notice of the date any particular guideline was adopted and to consider other relevant medical and scientific information that becomes available after that date. It also would be prudent to consider whether intellectual property interests may restrict the performance of certain tests and other procedures.The American College of Medical Genetics and Genomics (ACMG) previously developed guidance for the interpretation of sequence variants.1 In the past decade, sequencing technology has evolved rapidly with the advent of high-throughput next-generation sequencing. By adopting and leveraging next-generation sequencing, clinical laboratories are now performing an ever-increasing catalogue of genetic testing spanning genotyping, single genes, gene panels, exomes, genomes, transcriptomes, and epigenetic assays for genetic disorders. By virtue of increased complexity, this shift in genetic testing has been accompanied by new challenges in sequence interpretation. In this context the ACMG convened a workgroup in 2013 comprising representatives from the ACMG, the Association for Molecular Pathology (AMP), and the College of American Pathologists to revisit and revise the standards and guidelines for the interpretation of sequence variants. The group consisted of clinical laboratory directors and clinicians. This report represents expert opinion of the workgroup with input from ACMG, AMP, and College of American Pathologists stakeholders. These recommendations primarily apply to the breadth of genetic tests used in clinical laboratories, including genotyping, single genes, panels, exomes, and genomes. This report recommends the use of specific standard terminology—“pathogenic,” “likely pathogenic,” “uncertain significance,” “likely benign,” and “benign”—to describe variants identified in genes that cause Mendelian disorders. Moreover, this recommendation describes a process for classifying variants into these five categories based on criteria using typical types of variant evidence (e.g., population data, computational data, functional data, segregation data). Because of the increased complexity of analysis and interpretation of clinical genetic testing described in this report, the ACMG strongly recommends that clinical molecular genetic testing should be performed in a Clinical Laboratory Improvement Amendments–approved laboratory, with results interpreted by a board-certified clinical molecular geneticist or molecular genetic pathologist or the equivalent.Genet Med 17 5, 405–423.
Subfields: Cancer Research, Genetics, Computational Biology & Bioinformatics
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Cancer Research
- Peter D. Stenson
- David N. Cooper
- Gad Getz
- Jay Shendure
- Elaine R. Mardis
- Eric S. Lander
- Matthew Meyerson
- Mauno Vihinen
In Genetics
- Abhishek Niroula
- David N. Cooper
- Sharon E Plon
- Ninad Oak
- Rajarshi Ghosh
- Peter D. Stenson
- Mauno Vihinen
- Martin Kircher
In Computational Biology & Bioinformatics
- Burkhard Rost
- Nick V. Grishin
- UniProt Consortium
- Jimin Pei
- David N. Cooper
- Lisa N. Kinch
- Peter D. Stenson
- Martin Kircher
Citations in the corpus
- UniProt: the universal protein knowledgebase (2016, background): “With the increasing interest and progress in genomic-based medicine understanding the effects of variation on protein function is a key component of gene and variant curation (26,27).”
- Standards and Guidelines for the Interpretation and Reporting of Sequence Variants in Cancer: A Joint Consensus Recommendation of the Association for Molecular Pathology, American Society of Clinical Oncology, and College of American Pathologists. (2017, methodology): “Categorization and interpretation of tier IV variants may refer to recently published ACMG/ AMP standards and guidelines for the interpretation of germline sequence variants.(14)”
- Polygenic prediction of weight and obesity trajectories from birth to adulthood (2019, positive): “, 2005), a clinical laboratory geneticist on our team who was blinded to participant phenotypes classified each of the 24 observed MC4R variants according to current clinical guidelines (Richards et al., 2015), integrating information from population allele frequency data, computational prediction a”
- Genome-wide prediction of disease variants with a deep protein language model (2022, background): “Functionalization of VUS continues to serve a pressing need given their high prevalence in clinical sequencing efforts [10], which prevents many patients from receiving a clear diagnosis [2, 41–43].”
- Improving genetic diagnosis in Mendelian disease with transcriptome sequencing (2016, neutral): “Synonymous and missense variants in large, variation-rich genes, such as TTN, are exceptionally challenging to interpret and are often filtered out in DNA sequencing pipelines (23, 24).”
- Adaptation and Validation of the ACMG/AMP variant classification framework for MYH7-associated inherited cardiomyopathies: Recommendations by ClinGen’s Inherited Cardiomyopathy Expert Panel (2018, neutral): “Results: Adjustments represented disease-/gene-informed specifications (12) or strength adjustments of existing rules (5).”
- Multiplex Assessment of Protein Variant Abundance by Massively Parallel Sequencing (2018, methodology): “Indeed, the American College of Medical Genetics suggests that well-established functional assays can provide strong evidence of pathogenicity 40 .”
- CIViC is a community knowledgebase for expert crowdsourcing the clinical interpretation of variants in cancer (2017, background): “…the Association for Molecular Pathology (AMP) recently reported on the variability among nine laboratories in clinical interpretations of germline variants relevant to Mendelian diseases 21 , a field where the ACMG–AMP have proposed detailed standards and guidelines for variant classification 22 .”
- OncoKB: A Precision Oncology Knowledge Base (2017, background): “While multiple classification systems exist for the annotation of germline variants 60,61 , efforts to define the clinical utility of somatic alterations have been limited to established biomarkers 62–64 and prior efforts have often classified actionability as a binary variable resulting in the…”
- ClinVar: public archive of interpretations of clinically relevant variants (2015, background): “Clinical significance terms include the five terms recommended by ACMG for Mendelian diseases (5).”
- Mutation severity spectrum of rare alleles in the human genome is predictive of disease type (2019, methodology): “It should be noted that errors or inconsistencies with other databases could be present in ClinVar interpretations, especially the categories of “Likely pathogenic” and “Likely benign”, where the ACMG’s recommended confidence level is greater than 90% certainty of being disease-causing and benign, r”